Stay updated with breaking news from Neil brewis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FS222 demonstrated early antitumor activity with one complete response and six disease stabilizations in patients with advanced solid tumorsCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 06, 2022 ....
On July 7, 2022, invoX Pharma Limited ("invoX"), a wholly owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK) commenced a cash tender offer for all of the issued and ....
Unique Structure and Tetravalency of FS118 Is Required to Modulate LAG-3 Cell Surface ExpressionCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 08, 2022(NASDAQ: FSTX), a clinical-stage biopharmaceutical ....
F-star Therapeutics, Inc.: Study Published in Nature Shows F-Star s STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy SB 11285 is a Second Generation STING Agonist Delivered Intravenously CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 19, 2021. The study entitled STING enhances cell death through regulation of reactive oxygen species and DNA damage demonstrates that systemic administration of a STING agonist in combination with radiation in a preclinical model enhances local control in Head and Neck Squamous Cell Carcinoma (HNSCC) and suggests that STING expression in the tumor is required for maximal therapeutic benefit. The studies described in this paper demonstrate that systemic administration of SB 11285, a novel STING agonist, in combination with radiation, enhances the antitumor effects in animal models of HNSCC. Furthermore, STING expression in the tumor can be used as a predictive biomarker and a combination of radiation with ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Study Published in Nature Shows F-Star’s STING Agonist SB 11285 Enhances Preclinical Efficacy . F-star Therapeutics, Inc.April 19, 2021 GMT SB 11285 in Combination with Radiation is More Effective than Either as Monotherapy in a Murine Tumor Model SB 11285 is a Second Generation STING Agonist Delivered Intravenously CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced the publication of a new study, conducted by Yale University and F-star, of its second generation STING agonist, SB 11285, in the current issue of ....